ProtTech Funding: How Much Did They Raise & Key Investors

How Much Did ProtTech Raise?
Funding & Key Investors

ProtTech has successfully secured a significant capital injection, bringing its total funding to $43K. This latest financing round, which contributed $43K in substantial expansion capital, underscores the firm's robust position within the competitive bioanalytical services sector. By leveraging this investment, the company is well-positioned to accelerate its operational capabilities and expand its footprint in the pharmaceutical and biotechnology research landscape.

The recent infusion of resources marks a pivotal moment for the organization as it transitions into a more mature phase of its lifecycle. With a focus on scaling its high-throughput analytical infrastructure, ProtTech is poised to meet the increasing demand for sophisticated drug discovery support services, ensuring that its clients receive high-quality, cost-effective data solutions.

What is ProtTech?

ProtTech

Business Services

Research & Development

ProtTech Analytical LLC operates as a specialized contract bioanalytical laboratory, providing critical support to the pharmaceutical, biotechnology, and academic sectors. The company distinguishes itself through deep expertise in analytical chemistry, drug metabolism and pharmacokinetics (DMPK), and protein characterization. By utilizing advanced liquid chromatography-tandem mass spectrometry (LC-MS/MS) platforms, ProtTech delivers sensitive and rugged analytical methods essential for quantifying drugs and metabolites in complex biological matrices.

Beyond standard analytical services, the firm offers comprehensive in-vitro ADME packages and high-throughput biomarker assays. This technical versatility allows ProtTech to support researchers across all stages of drug discovery and development, from early-stage lead optimization to late-stage clinical support. Their commitment to flexible business operations and scientific rigor positions them as a vital partner for organizations seeking to navigate the complexities of modern drug development.

How much funding has ProtTech raised?

ProtTech has raised a total of $43K across 1 funding round:

2021

Debt

$43K

Debt (2021): $43K with participation from PPP

Key Investors in ProtTech

PPP

Public-Private Partnership

What's next for ProtTech?

Looking ahead, the strategic deployment of this capital will likely focus on enhancing the company's technological stack and expanding its laboratory capacity to accommodate larger study volumes. As the pharmaceutical industry continues to prioritize outsourcing for specialized analytical tasks, ProtTech is strategically aligned to capture additional market share. Future growth initiatives will likely involve the integration of more automated sample preparation techniques and the expansion of their biomarker discovery portfolio, further cementing their reputation as a leader in bioanalytical excellence. The firm remains committed to maintaining its competitive edge by balancing high-quality scientific output with the operational agility required by its diverse client base.

See full ProtTech company page

See More Financial Insights